Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies

Hagop M. Kantarjian, Jorge E. Cortes, Jacob M. Rowe, Razelle Kurzrock

Research output: Contribution to journalArticle

Abstract

Progress in molecular biology over the past several years has advanced our understanding of the pathology of leukemia. Researchers have identified a long list of the cytogenetic and molecular abnormalities associated with these diseases. However, a significant unmet need remains for medical therapies for leukemia, especially in older patients.

Original languageEnglish (US)
Pages (from-to)36-38
Number of pages3
JournalSeminars in Hematology
Volume39
Issue number3 SUPPL. 2
DOIs
StatePublished - Jul 2002
Externally publishedYes

Fingerprint

Farnesyltranstransferase
Hematologic Neoplasms
Leukemia
Chromosome Aberrations
Molecular Biology
Research Personnel
Pathology
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies. / Kantarjian, Hagop M.; Cortes, Jorge E.; Rowe, Jacob M.; Kurzrock, Razelle.

In: Seminars in Hematology, Vol. 39, No. 3 SUPPL. 2, 07.2002, p. 36-38.

Research output: Contribution to journalArticle

Kantarjian, Hagop M. ; Cortes, Jorge E. ; Rowe, Jacob M. ; Kurzrock, Razelle. / Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies. In: Seminars in Hematology. 2002 ; Vol. 39, No. 3 SUPPL. 2. pp. 36-38.
@article{ebe6626af89d4222961e42f0a271135c,
title = "Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies",
abstract = "Progress in molecular biology over the past several years has advanced our understanding of the pathology of leukemia. Researchers have identified a long list of the cytogenetic and molecular abnormalities associated with these diseases. However, a significant unmet need remains for medical therapies for leukemia, especially in older patients.",
author = "Kantarjian, {Hagop M.} and Cortes, {Jorge E.} and Rowe, {Jacob M.} and Razelle Kurzrock",
year = "2002",
month = "7",
doi = "10.1053/shem.2002.35986",
language = "English (US)",
volume = "39",
pages = "36--38",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 2",

}

TY - JOUR

T1 - Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies

AU - Kantarjian, Hagop M.

AU - Cortes, Jorge E.

AU - Rowe, Jacob M.

AU - Kurzrock, Razelle

PY - 2002/7

Y1 - 2002/7

N2 - Progress in molecular biology over the past several years has advanced our understanding of the pathology of leukemia. Researchers have identified a long list of the cytogenetic and molecular abnormalities associated with these diseases. However, a significant unmet need remains for medical therapies for leukemia, especially in older patients.

AB - Progress in molecular biology over the past several years has advanced our understanding of the pathology of leukemia. Researchers have identified a long list of the cytogenetic and molecular abnormalities associated with these diseases. However, a significant unmet need remains for medical therapies for leukemia, especially in older patients.

UR - http://www.scopus.com/inward/record.url?scp=0036655776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036655776&partnerID=8YFLogxK

U2 - 10.1053/shem.2002.35986

DO - 10.1053/shem.2002.35986

M3 - Article

C2 - 12214292

AN - SCOPUS:0036655776

VL - 39

SP - 36

EP - 38

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 3 SUPPL. 2

ER -